NEW YORK, Sept. 20 – Hybrigen and Bionomics Limited have signed a letter of intent to negotiate a partnership to study a pair of genes linked to breast cancer, the companies said on Thursday.

The target-discovery program will study the genes, TSG18 and BNO1, using genetic data identified and patented by Adelaide, Australia-based Bionomics, the firms said in a statement. For its part, Hybrigen, based in Dallas, will use its own proprietary proteomic technologies to discover drug targets that interact with those genes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.